Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

This study has been terminated.
(Early end of enrolment with regards to difficulty met to enrol patients .)
Information provided by (Responsible Party):
Steba Biotech S.A. Identifier:
First received: September 10, 2009
Last updated: April 14, 2016
Last verified: April 2016
The aim of this study is to evaluate the safety of Vascular Targeted Photodynamic therapy with WST11 in patients with non-resectable or inoperable biliary carcinoma.

Condition Intervention Phase
Drug: WST11
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Safety and Efficacy of WST11-mediated Vascular Targeted Photodynamic Therapy in Non-resectable or Inoperable Cholangiocarcinoma

Resource links provided by NLM:

Further study details as provided by Steba Biotech S.A.:

Primary Outcome Measures:
  • Evaluation of the safety based on analysis of adverse events , clinical laboratory tests, electrocardiogram, physical examination, absence of local or general complications and phototoxicity of WST11 in inoperable or non resectable cholangiocarcinoma [ Time Frame: Patient inclusion - Month 6 ]

Secondary Outcome Measures:
  • Evaluation of the antitumor efficacy of WST11-mediated VTP therapy by comparing the objective response rate on the tumor. [ Time Frame: Month 1, Month 3 & Month 6 ]
  • Evaluation of the effect of WST11-mediated VTP therapy on cholestasis and on the incidence of biliary complications of obstructive origin. [ Time Frame: Month 1, Month 3 & Month 6 ]
  • Evaluation of the effect of treatment on patient quality of life QLQ-C30. [ Time Frame: Month 1, Month 3 & Month 6 ]
  • Evaluation of the global survival after WST11-mediated VTP [ Time Frame: Month 6 ]

Enrollment: 8
Study Start Date: September 2009
Study Completion Date: September 2012
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: WST11
Treatment with WST11-mediated VTP
Drug: WST11
WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
Other Name: WST11-mediated VTP

Detailed Description:

This is an open-label, prospective, multicentre, phase IIa study, evaluating a new therapeutic agent in the management of patients suffering from inoperable or non resectable biliary carcinoma. The patients will receive the dose of WST11 according to order of inclusion. The first 3 patients will receive 2.5 mg/kg. In the absence of toxicity, the following 9 patients will receive the dose of 5 mg/kg.

The patient is to receive anesthesia. WST11-mediated therapy will consist of the combination of single IV administration of WST11 at doses of 2.5mg/kg or 5mg/kg, using 753nm laser light at a fixed power of (150mW/cm) and light energy (200 J/cm) delivered through a diffusing fiber. The fiber is introduced in a transparent standard ERCP catheter and positioned under radioscopy in front of the lesion.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient having signed the consent form to take part in the study
  • Patient aged over 18 years, with no upper age limit
  • Patient with histologically proven cholangiocarcinoma
  • Patient with cholangiocarcinoma, inoperable or non resectable owing to extension, age or concomitant diseases
  • Bilirubin level decrease of more than 50% after stent insertion compared to base level
  • Patient with a WHO Performance Scale ≤ 2
  • Patient in whom efficient drainage is performed by means of a plastic biliary stent endoscopically or radiologically
  • Patient capable of completing the quality of life questionnaires
  • Women of child-bearing potential must have a negative pregnancy test, and must thereafter prove to be using acceptable contraception (oral contraceptive pill, hormone patches, or IUD)

Exclusion Criteria:

  • Absence of consent to take part in the study
  • Patient with operable biliary carcinoma
  • Class ASA IV patients
  • Patients presenting clinical and laboratory signs of biliary infection
  • Absence of bilirubin decrease after stent insertion
  • Patients with extrinsic biliary compression
  • Patients already having received or currently receiving radiotherapy or chemotherapy for cholangiocarcinoma or needing to be treated during the first month of the follow-up
  • Known metastatic lesions
  • Patients having received immediate treatment by insertion of a metal stent
  • Patients with porphyria or known hypersensitivity to porphyrins (contraindication to WST11)
  • Patient receiving prohibited treatment at the time of inclusion in the study
  • Pregnant or breast-feeding women
  • Non-menopausal women not using effective contraception
  • Majors under protection as per the French Public Health Code
  • Persons not registered with or covered by a social security system
  • Persons in an exclusion period relative to other biomedical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00975039

Clinique de l'Alma
Paris, France
Sponsors and Collaborators
Steba Biotech S.A.
Principal Investigator: Emmanuel Ben Soussan, MD Clinique de l'Alma
  More Information

Responsible Party: Steba Biotech S.A. Identifier: NCT00975039     History of Changes
Other Study ID Numbers: CLIN904 CCM201
Study First Received: September 10, 2009
Last Updated: April 14, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Steba Biotech S.A.:
Inoperable Cholangiocarcinoma
Non-resectable Cholangiocarcinoma

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms processed this record on May 22, 2017